VCNX VACCINEX, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1205922 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.4%
TTM net income YoY8.0%
TTM EPS YoY79.7%
Revenue 3-yr CAGR-12.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,117.3%
Net margin-3,100.5%
FCF margin-2,696.8%
EBITDA margin-3,101.8%
Returns
ROE—
ROA-598.5%
ROIC (approx.)—
Asset turnover0.19x
Leverage & solvency
Liabilities / assets195.8%
Debt / equity—
Current ratio0.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-78.6%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $601,000 | $570,000 | $275,000 | $900,000 | $625,000 |
| Cost of revenue | — | — | — | — | $2,000 |
| Gross profit | — | — | — | — | $623,000 |
| R&D expense | $12.54M | $16.57M | $13.98M | $17.16M | $21.55M |
| SG&A expense | $6.79M | $6.88M | $6.20M | $6.23M | $7.41M |
| Operating income | -$18.73M | -$22.89M | -$19.91M | -$22.49M | -$28.33M |
| Interest expense | $2,000 | $1,000 | $2,000 | $809,000 | $489,000 |
| Pretax income | -$18.63M | -$20.25M | -$19.82M | -$22.38M | -$28.85M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.63M | -$20.25M | -$19.82M | -$22.38M | -$28.85M |
| EBITDA | -$18.64M | -$22.77M | -$19.70M | -$22.32M | -$28.02M |
| EPS (basic) | -8.88 | -43.68 | -98.05 | -0.78 | -1.54 |
| EPS (diluted) | -8.88 | -43.68 | -98.05 | -0.78 | -1.54 |
| Weighted avg. shares (diluted) | 2.10M | 463,653 | 202,082 | 28.85M | 18.79M |
| Balance sheet | |||||
| Cash & equivalents | $1.11M | $1.53M | $6.39M | $8.59M | $10.60M |
| Receivables | $838,000 | $961,000 | $175,000 | — | $157,000 |
| Current assets | $2.53M | $3.35M | $7.48M | $9.40M | $11.29M |
| PP&E, net | $65,000 | $136,000 | $189,000 | $297,000 | $416,000 |
| Total assets | $2.60M | $3.63M | $7.98M | $9.84M | $11.70M |
| Current liabilities | $5.08M | $5.92M | $2.54M | $2.26M | $13.18M |
| Short-term debt | $25,000 | $75,000 | $74,000 | $74,000 | — |
| Long-term debt | $0 | $26,000 | $101,000 | $175,000 | $1.13M |
| Total debt | $25,000 | $101,000 | $175,000 | $249,000 | $1.13M |
| Total liabilities | $5.08M | $5.94M | $2.78M | $2.43M | $14.31M |
| Shareholders' equity | -$2.49M | -$2.31M | $5.19M | $7.41M | -$26.57M |
| Net debt | -$1.08M | -$1.43M | -$6.22M | -$8.34M | -$9.46M |
| Shares outstanding | 2.68M | 892,617 | 237,527 | 30.80M | 22.39M |
| Cash flow statement | |||||
| Operating cash flow | -$16.19M | -$21.38M | -$19.07M | -$25.30M | -$28.65M |
| Capital expenditure | $22,000 | $67,000 | $99,000 | $32,000 | $290,000 |
| Free cash flow | -$16.21M | -$21.45M | -$19.17M | -$25.33M | -$28.94M |
| Investing cash flow | -$22,000 | -$67,000 | -$99,000 | -$32,000 | -$290,000 |
| Financing cash flow | $15.78M | $16.59M | $16.98M | $23.32M | $36.76M |
| Depreciation & amortization | $94,000 | $119,000 | $207,000 | $169,000 | $307,000 |
| Stock-based compensation | $341,000 | $474,000 | $545,000 | $541,000 | $732,000 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.